Sorrento Therapeutics Buy Hold or Sell Recommendation

SRNE -- USA Stock  

USD 2.57  0.03  1.15%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Sorrento Therapeutics is 'Cautious Hold'. Macroaxis provides Sorrento Therapeutics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SRNE positions. The advice algorithm takes into account all of Sorrento Therapeutics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from SRNE buy-and-hold prospective. Also please take a look at Sorrento Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Sorrento TherapeuticsBuy Sorrento Therapeutics
Cautious Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Sorrento Therapeutics has a mean deviation of 3.24, semi deviation of 0.0, standard deviation of 5.11, variance of 26.09, downside variance of 0.0 and semi variance of 0.0
We provide advice to complement the current expert consensus on Sorrento Therapeutics. Our dynamic recommendation engine harnesses multi - dimensional algorithm to analyze the corporation potential to grow using all technical and fundamental data available at the time. To make sure Sorrento Therapeutics is not overpriced, please validate all Sorrento Therapeutics fundamentals including its Net Income, Short Ratio, Working Capital, as well as the relationship between Debt to Equity and Beta . Please also confirm Sorrento Therapeutics Price to Sales to double-check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Sorrento Therapeutics Trading Alerts and Improvement Suggestions

Sorrento Therapeutics generates negative expected return over the last 30 days
Sorrento Therapeutics has high historical volatility and very poor performance
Sorrento Therapeutics has high likelihood to experience some financial distress in the next 2 years
Sorrento Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported previous year revenue of 21.09M. Net Loss for the year was (279.04M) with loss before overhead, payroll, taxes, and interest of (56.73M).
SORRENTO THERAPEU currently holds about 91.36M in cash with (147.86M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8.
Roughly 29.0% of the company outstanding shares are owned by corporate insiders

Sorrento Therapeutics current analysts recommendations

Target Median Price40.00
Target Mean Price40.00
Recommendation Mean2.00
Target High Price40.00
Number Of Analyst Opinions1
Target Low Price40.00

Sorrento Therapeutics Returns Distribution Density

Mean Return0.63Value At Risk6.62
Potential Upside5.18Standard Deviation5.11
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Commonwealth Equity Services LlcCommon Shares10.2 K27 K
Blackrock IncCommon Shares7.5 M35.8 M
Vanguard Group IncCommon Shares4.4 M20.9 M
State Street CorpCommon Shares2.1 M10.1 M
Northern Trust CorpCommon Shares1.3 M6.3 M
Geode Capital Management LlcCommon Shares1.3 M6.3 M
Bank Of New York Mellon CorpCommon Shares436.2 K2.1 M
Group One Trading LpCall Options231.4 K1.1 M
Susquehanna International Group LlpPut Options214.7 K1 M

Sorrento Therapeutics Greeks

α
Alpha over DOW
=0.71
β
Beta against DOW=0.59
σ
Overall volatility
=5.21
Ir
Information ratio =0.15

Sorrento Therapeutics Volatility Alert

Sorrento Therapeutics exhibits very low volatility with skewness of -0.97 and kurtosis of 7.19. However, we advise investors to further study Sorrento Therapeutics technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare Sorrento Therapeutics to competition

Sorrento Therapeutics Fundamental Vs Peers

FundamentalsSorrento TherapeuticsPeer Average
Return On Equity(181.35)% (0.31)%
Return On Asset(18.75)% (0.14)%
Current Valuation482.26M16.62B
Shares Owned by Insiders29.37% 10.09%
Shares Owned by Institutions25.91% 39.21%
Number of Shares Shorted15.51M4.71M
Price to Earning41.15X28.72X
Price to Book2.23X9.51X
Price to Sales14.94X11.42X
Revenue21.09M9.43B
Gross Profit(56.73M)27.38B
EBITDA(147.28M)3.9B
Net Income(279.04M)570.98M
Cash and Equivalents91.36M2.7B
Cash per Share0.80X5.01X
Total Debt288.5M5.32B
Debt to Equity244.20% 48.70%
Current Ratio1.60X2.16X
Book Value Per Share1.15X1.93K
Cash Flow from Operations(147.86M)971.22M
Short Ratio10.67X4.00X
Earnings Per Share(2.42)X3.12X
Price to Earnings To Growth(0.06)X4.89X
Number of Employees38218.84K
Beta2.7-0.15
Market Capitalization315.17M19.03B
Total Asset279.06M29.47B
Retained Earnings(162.3M)9.33B
Working Capital35.79M1.48B
Current Asset71.84M9.34B
Current Liabilities36.04M7.9B
Z Score0.68.72
Search macroaxis.com